Safety and early efficacy analysis of a novel combination of the PARP inhibitor veliparib (ABT-888) plus bendamustine and rituximab in patients with lymphoma Meeting Abstract


Authors: Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Moskowitz, C. H.; Noy, A.; Portlock, C. S.; Palomba, M. L.; Straus, D. J.; Younes, A.; Zelenetz, A. D.; Chen, A.; Little, R. F.; Fallon, F.; Whang, J. H.
Abstract Title: Safety and early efficacy analysis of a novel combination of the PARP inhibitor veliparib (ABT-888) plus bendamustine and rituximab in patients with lymphoma
Meeting Title: 56th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 124
Issue: 21
Meeting Dates: 2014 Dec 6-9
Meeting Location: San Francisco, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2014-12-06
Language: English
ACCESSION: WOS:000349242704065
PROVIDER: wos
DOI: 10.1182/blood.V124.21.1739.1739
Notes: Meeting Abstract: 1739 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Carol Portlock
    206 Portlock
  2. Craig Moskowitz
    407 Moskowitz
  3. Ariela Noy
    368 Noy
  4. Maria Lia Palomba
    439 Palomba
  5. Steven M Horwitz
    663 Horwitz
  6. Andrew D Zelenetz
    781 Zelenetz
  7. Alison Moskowitz
    354 Moskowitz
  8. Paul Hamlin
    291 Hamlin
  9. Matthew J Matasar
    292 Matasar
  10. David J Straus
    360 Straus
  11. Juho Patrick Whang
    3 Whang